Menin-MLL inhibitor 20, is a novel and irreversible menin-MLL interaction inhibitor with antitumor activities.

I-BET762 carboxylic acid (Molibresib carboxylic acid) is an I-BET762-based warhead ligand for conjugation reactions of PROTAC targeting on BET.

BAY-850 is a novel, potent and isoform selective inhibitor of ATPase family AAA domain-containing protein 2 (ATAD2) with an IC50 of 166 nM.

Bromosporine is a novel, potent and broad spectrum inhibitor against BET bromodomains with potential use as a chemical probe for bromodomain functional assays.

MI-463 is a novel potent & orally bioactive inhibitor of Menin-MLL interaction with an IC50 value of 15.3 nM.

ARV-825 (ARV825) is a novel and potent BRD4 degrader based on PROTAC (proteolysis-targeting chimera) technology, anticancer activity.

GSK2801 (GSK-2801) is a novel, orally bioavailable, selective, cell bioactive and acetyl-lysine competitive inhibitor of BAZ2A and BAZ2B bromodomains, which are the two closely related bromodomain containing proteins BAZ2A and BAZ2B constitute the central scaffolding protein of the nucleolar remodeling complex (NoRC) that regulates the expression of noncoding RNAs.

BAY-299 (BAY299) is a novel, highly potent, and selective dual inhibitor of BRD1 and TAF1 with important biological activity.

BI-7273 is a novel, potent, selective, and cell-permeable BRD9 inhibitor with IC50 and Kd of 19 and 0.75 nM, respectively; it also shows high effect on BRD7 with IC50 and Kd of 117 nM and 0.3 nM, respectively.

Mivebresib (formerly known as ABBV-075) is a novel potent bromodomain (BRD) inhibitor that is being tested in a Phase I study for the treatment of solid tumors.